The goal of the Fluent trial is to help patients with relapsing MS who are on fingolimod or have been taking fingolimod therapy for at least two years.
Fill out this form to learn if you may be eligible to participatein the study.
The EvergreenHealth Multiple Sclerosis Center is conducting a 12-month study of immune phenotype biomarkers in patients with Relapsing Multiple Sclerosis (RMS) after treatment with 0.5mg fingolimod.
Patients 18 years of age and older with a confirmed diagnosis of relapsing forms of Multiple Sclerosis.
Patients must be planning to start commercially prescribed fingolimod therapy 0.5mg per day OR must already be on commercially prescribed fingolimod 0.5mg per day continuously for two years or more.
Other inclusion and exclusion criteria may apply.
This study uses a two-cohort, nonrandomized, open-label, multicenter design.
The study consists of two periods: screening (up to four weeks) and fingolimod treatment period (baseline to 12 months). The total study duration is up to 13 months.
Follow-up visits will be conducted at three, six and 12 months.
Contact the EvergreenHealth Research Department hotline at 425.899.5385 and ask about the FLUENT study.